Getz Healthcare Partners with Subtle Medical to Improve Medical Imaging with AI-powered Technology

Getz Healthcare Pty Ltd announced today that they have partnered with Subtle Medical, a U.S-based healthcare technology company, to distribute the company’s artificial intelligence (AI)-based software solutions for faster and safer medical imaging. Subtle’s solutions could provide significant efficiency gains for hospitals and private radiology clinics within Australia and New Zealand, resulting in more timely patient access to critical PET and MRI imaging services.

Subtle Medical’s software solution, SubtlePET™, uses proprietary deep learning algorithms to denoise low count PET images from up to 75% lower radiotracer dose and faster scan times. SubtleMR™ uses increased sharpness and denoising to improve the image quality on up to 60% faster MRI exams. The solutions result in a broad range of benefits including faster scan times, lower radiation dose, improved image quality, higher scanner efficiency, and positive impacts on workflow and patient experience. Subtle’s solutions are compatible across all PET and MRI scanner brands, makes, and models, and seamlessly integrate into existing workflows.

“We are thrilled to be expanding patient access to our AI solutions. Our goal is to not only make medical imaging safer and more focused on the patient, but also help imaging institutions and radiologists achieve higher-quality imaging while running a more efficient operation. We are looking forward to a productive partnership with Getz,” said Josh Gurewitz, Chief Commercial Officer at Subtle Medical.

James Simkins, CEO, Getz Healthcare, added, “We are really excited to be partnering with Subtle Medical. We believe Subtle Medical’s software solution will bring tangible benefits to our customers and ultimately patients.” “The possibility for Subtle Medical’s software solutions to improve efficiency and image quality while extending the life of existing imaging systems is a real game changer for radiologists and patients in need of access to imaging. We are delighted to introduce this technology to Australia and New Zealand,” said Kimberly Hill, Managing Director of Getz Healthcare Australia & New Zealand.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.